OMEROS CORP Incurs New Financial Obligation on Feb 1, 2024

TL;DR

**Omeros just took on new debt or a major contract, watch for details on its impact.**

AI Summary

Omeros Corporation entered into a material definitive agreement and incurred a direct financial obligation on February 1, 2024. This 8-K filing, submitted on February 7, 2024, indicates a new financial commitment for the company, which could impact its liquidity and future operational flexibility. For investors, this matters because new obligations can affect a company's financial health, potentially influencing stock valuation and future growth prospects.

Why It Matters

This filing signals a new financial commitment for Omeros, which could impact its balance sheet and future cash flow, potentially affecting its ability to fund operations or pursue new projects.

Risk Assessment

Risk Level: medium — The filing indicates a new financial obligation without specifying the amount or terms, creating uncertainty about its potential impact on the company's financial health.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the nature, amount, and terms of the new material definitive agreement and financial obligation to assess its potential impact on Omeros's financial health and future prospects.

Key Players & Entities

• OMEROS CORPORATION (company) — the registrant filing the 8-K
• February 1, 2024 (date) — date of the earliest event reported
• February 7, 2024 (date) — date the 8-K was filed
• The Nasdaq Stock Market LLC (company) — exchange where Omeros common stock is registered
• 001-34475 (other) — Commission File Number for Omeros Corporation

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock , $0.01 par value per share OMER The Nasdaq
• $125 million — Agreement") under which Omeros received $125 million in cash in exchange for a portion of Om
• $115 million — and December 31, 2031. Omeros received $115 million in cash upon closing of the Amendment.
• $27.5 million — receive two milestone payments of up to $27.5 million each, payable in January 2026 and Janua

Filing Documents

• omer20230913_8k.htm (8-K) — 30KB
• 0001437749-24-003287.txt ( ) — 160KB
• omer-20240201.xsd (EX-101.SCH) — 3KB
• omer-20240201_def.xml (EX-101.DEF) — 11KB
• omer-20240201_lab.xml (EX-101.LAB) — 15KB
• omer-20240201_pre.xml (EX-101.PRE) — 11KB
• omer20230913_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Definitive Material Agreement.

03

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On February 1, 2024, Omeros Corporation ("Omeros" or the "Company") entered into an amended and restated royalty purchase agreement (the "Amendment") with DRI Healthcare Acquisitions LP ("DRI") providing for the acquisition by DRI of an expanded interest in certain royalty payments based on annual net sales of Omeros' former ophthalmologic product OMIDRIA (the "Purchased Receivables"). The Purchased Receivables comprise a portion of the royalties projected to be paid to Omeros under the terms of the Asset Purchase Agreement (the "Asset Purchase Agreement") among Omeros, Rayner Surgical Inc. ("Rayner") and Rayner Surgical Group Limited, pursuant to which the Company sold OMIDRIA and related business assets to Rayner in December 2021. On September 30, 2022, Omeros and DRI entered into a Royalty Purchase Agreement (the "Original Agreement") under which Omeros received $125 million in cash in exchange for a portion of Omeros' royalties on global net sales of OMIDRIA payable by Rayner between September 1, 2022 and December 31, 2030, subject to certain annual caps on the royalty amounts payable to DRI, with Omeros entitled to receive all royalties paid in excess of the applicable caps. On February 1, 2024, Omeros and DRI entered into the Amendment to effect the sale to DRI of an expanded interest in the OMIDRIA royalties. The Amendment eliminated the annual caps on royalty payments to which DRI is entitled and provides that DRI will now receive all royalties on U.S. net sales of OMIDRIA payable between January 1, 2024 and December 31, 2031. Omeros received $115 million in cash upon closing of the Amendment. Additionally, Omeros is eligible under the Amendment to receive two milestone payments of up to $27.5 million each, payable in January 2026 and January 2028, respectively, based on achievement of certain thresholds for U.S. net sales of OMI

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OMEROS CORPORATION Date: February 7, 2024 By: /s/ Gregory A. Demopulos Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR